KR930700104A - Inhibition of diseases mediated by the 5-lipoxygenase and cyclooxygenase pathways - Google Patents

Inhibition of diseases mediated by the 5-lipoxygenase and cyclooxygenase pathways

Info

Publication number
KR930700104A
KR930700104A KR1019920703188A KR920703188A KR930700104A KR 930700104 A KR930700104 A KR 930700104A KR 1019920703188 A KR1019920703188 A KR 1019920703188A KR 920703188 A KR920703188 A KR 920703188A KR 930700104 A KR930700104 A KR 930700104A
Authority
KR
South Korea
Prior art keywords
alkyl
alkenyl
substituents
pyridyl
thio
Prior art date
Application number
KR1019920703188A
Other languages
Korean (ko)
Inventor
레로이 아담스 제리
엘리어트 벤더 파울
프랜시스 갤라저 티모디
리챠드 헤이스 죤
퍼초녹 칼
죤 빌래니 안토니
Original Assignee
원본미기재
스미스클라인 비참 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 스미스클라인 비참 코포레이션 filed Critical 원본미기재
Publication of KR930700104A publication Critical patent/KR930700104A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

내용 없음.No content.

Description

5-리프옥시게나제 및 사이클로옥시게나제 경로 개재된 질병의 억제Inhibition of diseases mediated by the 5-lipoxygenase and cyclooxygenase pathways

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (31)

OPUFA 개재된 질병의 치료를 필요로 하는 환자에게 유효한 OPUFA 억제량의 일반식(I)의 화합물 또는 이의 약제학적으로 허용되는 염을 투여함을 특징으로 하여, 상기 환자에 있어서, OPUFA 개재된 질병을 치료하는 방법:In a patient in need of treatment for an OPUFA intervening disease, an effective amount of the OPUFA inhibitory compound of formula (I) or a pharmaceutically acceptable salt thereof is administered. How to treat: 상기식에서, W는 -CR5≡ CR7-, -N=CR7-, -S- 또는 -O-이고; R2, R3, R5및 R7는 독립적으로 수소 또는 C1-2알킬이고 R1및 R0중의 하나는 4-피리딜 또는 C1-4알킬-4-피리딜일 경우 알킬 치환체는 피리딘환의 2-위치 위치하여야 하고, R1및 R0중의 다른 하나는 (a) 페닐 또는 모노치환된 페닐[여기에서 상기 치환체는 C1-4알킬, 할로, 하이드록시, C1-4알콕시, C1-3알킬티오, C1-3알킬설피닐, C2-51-알케닐-1-티오, C2-51-알케닐-1-설피닐, C3-52-알케닐-1-티오, C3-52-알케닐-1-설피닐, C1-3알킬설포닐, C2-51-알케닐-1-설포닐, C3-52-알케닐-1-설포닐, C1-3알킬아미노, C1-3디알킬아미노, CF3, N-(1-3알칸아미도), N-(C1-3알킬)-N-(1-3알칸아미도), N-피롤리디노, N-피페리디노, 프로프-2-엔-1-옥시 또는 2,2,2-트리할로에톡시, 티올, 아실티오, 이티오아실, 티오카르바밀, 디티오카르바밀, 알킬카르보닐알킬티오, 카르브알콕시 알킬티오, 알콕시카르보닐티오, 알콕시티오노티오, 페닐티오, 페닐설피닐, 알콕시알킬티오, 알콕시알킬설피닐, 알킬티오알킬티오, Z, 또는 아실옥시알킬티오이다]이거나, (b) 디치환된 페닐(여기에서 상기 치환체는 독립적으로 C1-3알킬티오, C1-3알콕시, 할로, C1-4알킬, C1-3알킬아미노, N-(C1-3알킬)-N-(C1-3알칸아미도), C1-3디킬아미노, 아미노, N-피롤리디노 또는 N-피페리디노이다]이거나, (c) 디치환된 페닐(여기에서 상기 치환체중의 하나는 C1-3알콕시, 할로, CF3또는 C1-4알킬이고, 다른 치환체는 티올, 아실티오, 디티오아실, 티오카르바밀, 디티오카르바밀, 알킬카르보닐알킬티오, 카르브알콕시알킬티오, 알콕시카르보닐티오, 알콕시티오노티오, 페닐티오, 알콕시알킬티오, 알콕시알킬설피닐, 알킬티오알킬티오, Z, 또는 아실옥시알킬티오이다)이거나, (d) 디치환된 페닐(여기에서 상기 치환체중의 하나는 아미노, C1-3알킬아미노 또는 C1-3디알킬아미노이고, 다른 치환체는 C1-3알킬설피닐, C2-5-1-알케닐-1-티오, C2-5-1-알케닐-1-설피닐, C3-52-알케닐-1-티오, C3-52-알케닐-1-설피닐, 티올, 아실티오, 티티오아실, 티오카르바밀, 티티오카르바밀, 알킬카르보닐알킬티오, 카르브알콕시알킬티오, 알콕시카르보닐티오, 알콕시티오노티오, 페닐티오, 페닐설피닐, 알콕시알킬티오, 알콕시알킬설피닐, 알킬티오알킬티오, Z, 또는 아실옥시알킬티오이다)이거나, (e) 디치환된 페닐(여기에서 상기 치환체는 동일하고 할로, C1-3알콕시, C1-3알킬아미노, C1-3디알킬아미노, N-피롤리디노, N-피페리디노, 2,2,2-트리할로에톡시, 프로프-2-엔-1-옥시 또는 하이드록시, C1-3알킬티오, C1-3알킬설피닐, C1-3알킬-설포닐, C2-51-알케닐-1-티오, C2-5-1-알케닐-1-설피닐, C3-52-알케닐-1-티오, C3-52-알케닐-1-설피닐, 티올, 아실티오, 티티오아실, 티오카르바밀, 디티오-카르바밀, 킬카르보닐알킬티오, 카르브알콕시알킬티오, 알콕시카르보닐티오, 알콕시티오노티오, 페닐티오, 페닐설피닐, 알콕시알킬티오, 알콕시알킬설피닐, 알킬티오알킬티오, Z, 또는 아실옥시알킬티오중에서 선택되거나, 치환체가 함께 메틸렌 디옥시 그룹을 형성한다)이고; (f) 다음 일반식중의 하나의 잔기이다:Wherein W is -CR 5 ≡ CR 7- , -N = CR 7- , -S- or -O-; The alkyl substituent is pyridine when R 2 , R 3 , R 5 and R 7 are independently hydrogen or C 1-2 alkyl and one of R 1 and R 0 is 4-pyridyl or C 1-4 alkyl-4-pyridyl And the other of R 1 and R 0 is (a) phenyl or monosubstituted phenyl, wherein the substituents are C 1-4 alkyl, halo, hydroxy, C 1-4 alkoxy, C 1-3 alkylthio, C 1-3 alkylsulfinyl, C 2-5 1-alkenyl-1-thio, C 2-5 1-alkenyl-1-sulfinyl, C 3-5 2-alkenyl- 1-thio, C 3-5 2-alkenyl-1-sulfinyl, C 1-3 alkylsulfonyl, C 2-5 1-alkenyl-1-sulfonyl, C 3-5 2-alkenyl-1 -Sulfonyl, C 1-3 alkylamino, C 1-3 dialkylamino, CF 3 , N- ( 1-3 alkanamido), N- (C 1-3 alkyl) -N- ( 1-3 alkanes Amido), N-pyrrolidino, N-piperidino, prop-2-en-1-oxy or 2,2,2-trihaloethoxy, thiol, acylthio, itioacyl, thiocar Bamil, dithiocarbamyl, alkylcarbonylalkylthio, carvalkoxy Or chelate, alkoxycarbonylthio, alkoxythiothiothio, phenylthio, phenylsulfinyl, alkoxyalkylthio, alkoxyalkylsulfinyl, alkylthioalkylthio, Z, or acyloxyalkylthio; or (b) disubstituted Phenyl, wherein the substituents are independently C 1-3 alkylthio, C 1-3 alkoxy, halo, C 1-4 alkyl, C 1-3 alkylamino, N- (C 1-3 alkyl) -N- (C 1-3 alkanamido), C 1-3 dialkylamino, amino, N-pyrrolidino or N-piperidino] or (c) disubstituted phenyl, wherein one of the above substituents is C 1-3 alkoxy, halo, CF 3 or C 1-4 alkyl, other substituents are thiols, acylthio, dithioacyl, thiocarbamyl, dithiocarbamyl, alkylcarbonylalkylthio, carvalkoxyalkylthio , Alkoxycarbonylthio, alkoxythiothiothio, phenylthio, alkoxyalkylthio, alkoxyalkylsulfinyl, alkylthioalkylthio, Z, or acyloxyalkylthio) Or, (d) disubstituted phenyl (wherein one of the body weight is substituted amino, C 1-3 alkyl amino or C 1-3 dialkylamino, and the other substituents are C 1-3 alkyl sulfinyl, C 2- 5-1 -alkenyl-1-thio, C 2-5 -1-alkenyl-1-sulfinyl, C 3-5 2-alkenyl-1-thio, C 3-5 2-alkenyl-1- Sulfinyl, thiols, acylthio, thithioacyl, thiocarbamyl, thithiocarbamyl, alkylcarbonylalkylthio, carvalkoxyalkylthio, alkoxycarbonylthio, alkoxythiothiothio, phenylthio, phenylsulfinyl, Alkoxyalkylthio, alkoxyalkylsulfinyl, alkylthioalkylthio, Z, or acyloxyalkylthio) or (e) disubstituted phenyl, wherein the substituents are the same and halo, C 1-3 alkoxy, C 1 -3 alkylamino, C 1-3 dialkylamino, N-pyrrolidino, N-piperidino, 2,2,2-trihaloethoxy, prop-2-en-1-oxy or hydroxy , C 1-3 alkylthio, C 1-3 alkylsulfinyl, C 1-3 alkyl-sulfonyl, C 2-5 1-alkenyl-1-thio, C 2-5 -1-alkenyl-1-sulfinyl, C 3-5 2-alkenyl-1-thio, C 3-5 2-alkenyl-1 Sulfinyl, thiols, acylthio, thithioacyl, thiocarbamyl, dithio-carbamyl, chelcylylthiothio, carvalkoxyalkylthio, alkoxycarbonylthio, alkoxythiothiothio, phenylthio, phenylsulfy N, alkoxyalkylthio, alkoxyalkylsulfinyl, alkylthioalkylthio, Z, or acyloxyalkylthio, or substituents together form a methylene dioxy group); (f) is a residue of one of the following general formulas: 상기식에서, t는 0 또는 1이고; R4및 R6는 독립적으로 수소, C1-9알킬, 아릴 또는 헤테로아릴이고; Z는 -S-(CR4R6)t-S-Z1이고; Z1는 C1-9알킬, 아릴 또는 헤테로아릴이다.Wherein t is 0 or 1; R 4 and R 6 are independently hydrogen, C 1-9 alkyl, aryl or heteroaryl; Z is -S- (CR 4 R 6 ) t -SZ 1 ; Z 1 is C 1-9 alkyl, aryl or heteroaryl. 제1항에 있어서, W가 -CR5= CR7-, -N=CR7-, -S- 또는 -O-이고; R2및 R3은 수소이고; R1및 R0중의 하나가 4-피리딜 또는 C1-2알킬-4-피리딜이며, 단, R1이 C1-2알킬-4-피리딜일 경우 알킬 치환체는 피리딘환의 2-위치에 위치하여야 하고, R1및 R0중의 다른 하나가 (a) 모노치환된 페닐(여기에서 상기치환체는 할로, C1-3알킬아미노, C1-3디알킬아미노, 티올, 하이드록시, C1-3알콕시, C1-3알킬티오, C1-3알킬설피닐, 아실옥시알킬티오 또는 아실티오이다)이거나; (b) 디치환된 페닐(여기에서 상기 치환체는 독립적으로 C1-3알킬티오, C1-3알콕시, C1-3알킬아미노, C1-3디알킬아미노, N-피롤리디노 또는 N-피페리디노이다)이거나; (c) 디치한된 페닐(여기에서 상기 치환체중의 하나는 C1-3알킬설피닐, 아실티오, 1-아실옥시-1-알킬티오이고 다른 하나는 C1-3알콕시 또는 할로이다)이거나; (d) 디치환된 페닐(여기에서 상기 치환체중의 하나는 C1-3알킬아미노, C1-3디알킬아미노이고 다른하나는 아실티오, 알킬설피닐, 페닐설피닐 또는 아실옥시알킬키오중에서 선택된다)이거나; (e) 디치환된 페닐(여기에서 치환체는 동일하고 C1-3알콕시, C1-2알킬설피닐, C2-31-알케닐-1-티오, 2-프로페닐-1-티오 또는 1-아실옥시-1-알킬티오이거나 치환체가 함께 메틸렌 디옥시그룹을 형성한다)인 방법.The compound of claim 1, wherein W is —CR 5 = CR 7 —, —N═CR 7 —, —S— or —O—; R 2 and R 3 are hydrogen; Wherein one of R 1 and R 0 is 4-pyridyl or C 1-2 alkyl-4-pyridyl, provided that when R 1 is C 1-2 alkyl-4-pyridyl the alkyl substituent is at the 2-position of the pyridine ring And one of R 1 and R 0 is (a) monosubstituted phenyl, wherein said substituent is halo, C 1-3 alkylamino, C 1-3 dialkylamino, thiol, hydroxy, C 1 -3 alkoxy, C 1-3 alkylthio, C 1-3 alkylsulfinyl, acyloxyalkylthio or acylthio); (b) disubstituted phenyl, wherein the substituents are independently C 1-3 alkylthio, C 1-3 alkoxy, C 1-3 alkylamino, C 1-3 dialkylamino, N-pyrrolidino or N -Piperidino); (c) divalent phenyl, wherein one of the substituents is C 1-3 alkylsulfinyl, acylthio, 1-acyloxy-1-alkylthio and the other is C 1-3 alkoxy or halo ; (d) disubstituted phenyl, wherein one of said substituents is C 1-3 alkylamino, C 1-3 dialkylamino and the other is acylthio, alkylsulfinyl, phenylsulfinyl or acyloxyalkylchio Is selected); (e) disubstituted phenyl, wherein the substituents are the same and are C 1-3 alkoxy, C 1-2 alkylsulfinyl, C 2-3 1-alkenyl-1-thio, 2-propenyl-1-thio or 1-acyloxy-1-alkylthio or substituents together form a methylene dioxy group). 제2항에 있어서, W가 -CR5-CR7-, -N=CR7-, -S- 또는 -O-이고; R2및 R3은 수소이고; R1및 R0중의 하나가 4-피리딜 또는 C1-2알킬-4-피리딜이며, 단, R1이 C1-2알킬-4-피리딜일 경우 알킬 치환체는 피리딘환의 2-위치에 위치하여야 하고, R1및 R0중의 다른 하나가 (a) 모노치환된 페닐(여기에서 상기치환체는 할로, C1-3알콕시, C1-3알킬티오, C1-3알킬설피닐, 아실옥시알킬티오 또는 아실티오이다)이거나; (b) 디치환된 페닐(여기에서 상기 치환체는 독립적으로 C1-3알킬틸오, C1-3알콕시, C1-3알킬아미노, 또는 C1-3디알킬아미노이다)이거나; (c) 디치환된 페닐(여기에서 상기 치환체중의 하나는 C1-3알킬설피닐, 아실티오, 1-아실옥시-1-알킬티오이고 다른 하나는 C1-3알콕시 또는 할로이다)이거나; (d) 디치환된 페닐(여기에서 상기 치환체중의 하나는 C1-3알킬아미노, C1-3디알킬아미노이고 다른하나는 아실티오, 알킬설피닐, 페닐설피닐 또는 아실옥시알킬티오중에서 선택된다)이거나; (e) 디치환된 페닐(여기에서 치환체는 동일하고 C1-3알콕시, C1-2알킬설피닐, C2-31-알케닐-1-티오, 2-프로페닐-1-티오 또는 1-아실옥시-1-알킬티오이거나 치환체가 함께 메틸렌 디옥시그룹을 형성한다)인 방법.The method of claim 2, wherein, W is -CR 5- CR 7 -, -N = CR 7 -, -S- or -O-; R 2 and R 3 are hydrogen; Wherein one of R 1 and R 0 is 4-pyridyl or C 1-2 alkyl-4-pyridyl, provided that when R 1 is C 1-2 alkyl-4-pyridyl the alkyl substituent is at the 2-position of the pyridine ring And one of R 1 and R 0 is (a) monosubstituted phenyl, wherein said substituent is halo, C 1-3 alkoxy, C 1-3 alkylthio, C 1-3 alkylsulfinyl, acyl Oxyalkylthio or acylthio); (b) disubstituted phenyl, wherein the substituents are independently C 1-3 alkylthylo, C 1-3 alkoxy, C 1-3 alkylamino, or C 1-3 dialkylamino; (c) disubstituted phenyl, wherein one of the substituents is C 1-3 alkylsulfinyl, acylthio, 1-acyloxy-1-alkylthio and the other is C 1-3 alkoxy or halo ; (d) disubstituted phenyl, wherein one of said substituents is C 1-3 alkylamino, C 1-3 dialkylamino and the other is acylthio, alkylsulfinyl, phenylsulfinyl or acyloxyalkylthio Is selected); (e) disubstituted phenyl, wherein the substituents are the same and are C 1-3 alkoxy, C 1-2 alkylsulfinyl, C 2-3 1-alkenyl-1-thio, 2-propenyl-1-thio or 1-acyloxy-1-alkylthio or substituents together form a methylene dioxy group). 제2항에 있어서, 일반식(I)의 화합물이 2-(4-메톡시페닐)-3-(4-피리딜)-이미다조[1, 2-a]피리딘인 방법.The method of claim 2, wherein the compound of formula (I) is 2- (4-methoxyphenyl) -3- (4-pyridyl) -imidazo [1,2-a] pyridine. 제1항 내지 제4항중 어느 한 항에 있어서, 효소 5-리프옥시게나제가 억제되는 방법.The method of any one of claims 1 to 4, wherein the enzyme 5-lipoxygenase is inhibited. 제5항에 있어서, OPUFA 개재된 질병이 관절염, 류머티스성 관절염, 골관절염, 진통성비염, 건선, 피부염, 국소빈혈 유도된 심근상처, 국소관류상처, 통풍, 천식, 성인호흡장애증후군, 아테롬성 동맥경화증, 염증성 장질환, 발작, 척추코드상처 또는 외상뇌상처인 방법.The disease of claim 5, wherein the OPUFA mediated disease is arthritis, rheumatoid arthritis, osteoarthritis, analgesic rhinitis, psoriasis, dermatitis, ischemia-induced myocardial wound, local perfusion wound, gout, asthma, adult respiratory distress syndrome, atherosclerosis , Inflammatory bowel disease, seizures, spinal cord wounds or traumatic brain wounds. 사이클로옥시게나제 경로 개재된 질병의 치료를 필요로 하는 환자에게 유효한 비독성의 사이클로 옥시게 나제 경로 억제량의 일반식(I)의 화합물 또는 이의 약제학적으로 허용되는 염을 투여함을 특징으로 하여, 상기 환자에 있어서 사이클로옥시게나제 경로 개재된 질병을 치료하는 방법:Characterized by administering to a patient in need of treatment of a disease interrupted by a cyclooxygenase pathway an effective non-toxic cyclooxygenase pathway inhibitory amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof A method for treating a disease mediated by a cyclooxygenase pathway in said patient: 상기식에서, W는 -CR5= CR7-, -N=CR7-, -S- 또는 -O-이고; R2, R3, R5및 R7는 독립적으로 수소 또는 C1-2알킬이고; R1및 R0중의 하나는 4-피리딜 또는 C1-4알킬-4-피리딜이며, 단, R1이 C1-4알킬-4-피리딜 경우 알킬 치환체는 피리딘환의 2-위치 위치하여야 하고, R1R0중의 다른 하나는 (a) 페닐 또는 모노치환된 페닐[여기에서 상기 치환체는 C1-4알킬, 할로, 하이드록시,; C1-4알콕시, C1-3알킬티오, C1-3알킬설피닐, C2-51-알케닐-1-티오, C2-51-알케닐-1-설피닐, C3-52-알케닐-1-티오, C3-52-알케닐-1-설피닐, C1-3알킬설포닐, C2-51-알케닐-1-설포닐, C3-52-알케닐-1-설포닐, C1-3알킬아미노, C1-3디알킬아미노, CF3, N-(C1-3알칸아미도), N-(C1-3알킬)-N-(C1-3알칸아미도), N-피롤리디노, N-피페리디노, 프로프-2-엔-1-옥시 또는 2,2,2-트리할로에톡시, 티올, 아실티오, 디티오아실, 티오카르바밀, 디티오카르바밀, 알킬카르보닐알킬티오, 카르브알콕시알킬티오, 알콕시카르보닐티오, 알콕시티오노티오, 페닐티오, 페닐설피닐, 알콕시알킬티오, 알콕시알킬설피닐, 페닐티오, 페닐설피닐, 알콕시알킬티오, 알콕시알킬설피닐, 알킬티오알킬티오, Z, 또는 아실옥시알킬티오이다]이거나; (b) 디치환된 페닐[여기에서 상기 치환체는 독립적으로 C1-3알킬티오, C1-3알콕시, 할로, C1-4알킬, C1-3알킬아미노, N-(C1-3알킬)-N-(C1-3알칸아미도), C1-3디알킬아미노, 아미노, N-피롤리디노 또는 N-피페리디노이다]이거나; (c) 디치환된 페닐(여기에서 상기 치환체중의 하나는 C1-3알콕시, 할로, CF3또는 C1-4알킬이고, 다른 치환체는 티올, 아실티오, 디티오아실, 티오카르바밀, 디티오카르바밀, 알킬카르보닐알킬티오, 카르브알콕시알킬티오, 알콕시카르보닐티오, 알콕시티오노티오, 페닐티오, 알콕시알킬티오, 알콕시알킬설피닐, 알킬티오알킬티오, Z, 또는 아실옥시알킬티오이다)이거나; (d) 디치환된 페닐(여기에서 상기 치환체중의 하나는 아미노, C1-3알킬아미노 또는 C1-3디알킬아미노이고, 다른 치환체는 C1-3알킬설피닐, C2-5-1-알케닐-1-티오, C2-5-1-알케닐-1-설피닐, C3-52-알케닐-1-티오, C3-52-알케닐-1-설피닐, 티올, 아실티오, 디티오아실, 티오카르바밀, 디티오카르바밀, 알킬카르보닐알킬티오, 카르브알콕시알킬티오, 알콕시카르보닐티오, 알콕시티오노티오, 페닐티오, 페닐설피닐, 알콕시알킬티오, 알콕시알킬설피닐, 알킬티오알킬티오, Z, 또는 아실옥시알킬티오이다)이거나; (e) 디치환된 페닐(여기에서 상기 치환체는 동일하고 할로, C1-3알콕시, C1-3알킬아미노, C1-3디알킬아미노, N-피롤리디노, N-피페리디노, 2,2,2-트리할로에톡시, 프로프-2-엔-1-옥시 또는 하이드록시, C1-3알킬티오, C1-3알킬설피닐, C1-3알킬-설포닐, C2-51-알케닐-1-티오, C2-5-1-알케닐-1-설피닐, C3-52-알케닐-1-티오, C3-52-알케닐-1-설피닐, 티올, 아실티오, 디티오아실, 티오카르바밀, 디티오카르바밀, 알킬카르보닐알킬티오, 카르브알콕시알킬티오, 알콕시카르보닐티오, 알콕시티오노티오, 페닐티오, 페닐설피닐, 알콕시알킬티오, 알콕시알킬설피닐, 알킬티오알킬티오, Z, 또는 아실옥시알킬티오중에서 선택되거나; 치환체가 함께 메틸렌 디옥시 그룹을 형성한다)이고; (f) 다음 일반식중의 하나의 잔기이다:Wherein W is -CR 5 = CR 7- , -N = CR 7- , -S- or -O-; R 2 , R 3 , R 5 and R 7 are independently hydrogen or C 1-2 alkyl; One of R 1 and R 0 is 4-pyridyl or C 1-4 alkyl-4-pyridyl, provided that when R 1 is C 1-4 alkyl-4-pyridyl the alkyl substituent is the 2-position of the pyridine ring And the other of R 1 R 0 is (a) phenyl or monosubstituted phenyl, wherein the substituents are C 1-4 alkyl, halo, hydroxy ,; C 1-4 alkoxy, C 1-3 alkylthio, C 1-3 alkylsulfinyl, C 2-5 1-alkenyl-1-thio, C 2-5 1-alkenyl-1-sulfinyl, C 3 -5 2-alkenyl-1-thio, C 3-5 2-alkenyl-1-sulfinyl, C 1-3 alkylsulfonyl, C 2-5 1-alkenyl-1-sulfonyl, C 3- 5 2-alkenyl-1-sulfonyl, C 1-3 alkylamino, C 1-3 dialkylamino, CF 3 , N- (C 1-3 alkanamido), N- (C 1-3 alkyl) -N- (C 1-3 alkanamido), N-pyrrolidino, N-piperidino, prop-2-en-1-oxy or 2,2,2-trihaloethoxy, thiol, Acylthio, dithioacyl, thiocarbamyl, dithiocarbamyl, alkylcarbonylalkylthio, carboalkoxyalkylthio, alkoxycarbonylthio, alkoxythiothiothio, phenylthio, phenylsulfinyl, alkoxyalkylthio, alkoxy Alkylsulfinyl, phenylthio, phenylsulfinyl, alkoxyalkylthio, alkoxyalkylsulfinyl, alkylthioalkylthio, Z, or acyloxyalkylthio; (b) di-substituted phenyl, wherein the substituents are independently C 1-3 alkylthio, C 1-3 alkoxy, halo, C 1-4 alkyl, C 1-3 alkylamino, N- (C 1-3 Alkyl) -N- (C 1-3 alkanamido), C 1-3 dialkylamino, amino, N-pyrrolidino or N-piperidino]; (c) disubstituted phenyl, wherein one of the substituents is C 1-3 alkoxy, halo, CF 3 or C 1-4 alkyl, the other substituent is thiol, acylthio, dithioacyl, thiocarbamyl, Dithiocarbamyl, alkylcarbonylalkylthio, carboalkoxyalkylthio, alkoxycarbonylthio, alkoxythiothiothio, phenylthio, alkoxyalkylthio, alkoxyalkylsulfinyl, alkylthioalkylthio, Z, or acyloxyalkyl Thio); (d) disubstituted phenyl, wherein one of said substituents is amino, C 1-3 alkylamino or C 1-3 dialkylamino, and the other substituents are C 1-3 alkylsulfinyl, C 2-5- 1-alkenyl-1-thio, C 2-5 -1-alkenyl-1-sulfinyl, C 3-5 2-alkenyl-1-thio, C 3-5 2-alkenyl-1-sulfinyl , Thiol, acylthio, dithioacyl, thiocarbamyl, dithiocarbamyl, alkylcarbonylalkylthio, carbalkoxyalkylthio, alkoxycarbonylthio, alkoxythiothiothio, phenylthio, phenylsulfinyl, alkoxyalkyl Thio, alkoxyalkylsulfinyl, alkylthioalkylthio, Z, or acyloxyalkylthio); (e) disubstituted phenyl, wherein said substituents are the same and halo, C 1-3 alkoxy, C 1-3 alkylamino, C 1-3 dialkylamino, N-pyrrolidino, N-piperidino, 2,2,2-trihaloethoxy, prop-2-ene-1-oxy or hydroxy, C 1-3 alkylthio, C 1-3 alkylsulfinyl, C 1-3 alkyl-sulfonyl, C 2-5 1-alkenyl-1-thio, C 2-5 -1-alkenyl-1-sulfinyl, C 3-5 2-alkenyl-1-thio, C 3-5 2-alkenyl- 1-sulfinyl, thiol, acylthio, dithioacyl, thiocarbamyl, dithiocarbamyl, alkylcarbonylalkylthio, carvalkoxyalkylthio, alkoxycarbonylthio, alkoxythiothio, phenylthio, phenylsulfy N, alkoxyalkylthio, alkoxyalkylsulfinyl, alkylthioalkylthio, Z, or acyloxyalkylthio; substituents together form a methylene dioxy group); (f) is a residue of one of the following general formulas: 또는or 상기식에서, t는 0 또는 1이고; R4는 R6는 독립적으로 수소, C1-9알킬, 아릴 또는 헤테로아릴이고; Z는 -S-(CR4R6)t-S-Z1이고; Z1는 C1-9알킬, 아릴 또는 헤테로아릴이다.Wherein t is 0 or 1; R 4 is R 6 is independently hydrogen, C 1-9 alkyl, aryl or heteroaryl; Z is -S- (CR 4 R 6 ) t -SZ 1 ; Z 1 is C 1-9 alkyl, aryl or heteroaryl. 제7항에 있어서, W가는 -CR5=CR7-, -N=CR7-, -S- 또는 -O-이고, R2및 R3은 수소이고; R1및 R0중의 하나가 4-피리딜 또는 C1-2알킬-4-피리딜이며, 단, R1이 C1-2알킬-4-피리딜일 경우 알킬 치환체는 피리딘환의 2-위치에 위치하여야 하고, R1및 R0중의 다른 하나가 (a) 모노치환된 페닐(여기에서 상기 치환체는 할로, CF3, C1-3알킬아미노 C1-3디알칼아미노, 티올, 하이드록시, C1-3알콕시, C1-3알킬티오, C1-3알킬설피닐, 아실옥시알킬티오 또는 아실티오이다)이거나; (b) 디치환된 페닐(여기에서 상기 치환체는 독립적으로 C1-3알킬티오, C1-3알콕시, C1-3알킬아미노, C1-3디알킬아미노, N-피롤리디노 또는 N-피페리디노이다)이거나; (c) 디치환된 페닐(여기에서 상기 치환체중의 하나는 C1-3알킬설피닐, 아실티오, 1-아실옥시-1-알킬티오이고 다른하나는 C1-3알콕시 또는 할로이다)이거나; (d) 디치환된 페닐(여기에서 상기 치환체중의 하나는 C1-3알킬아미노, C1-3디알킬아미노이고 다른하나는 아실티오, 알킬설피닐, 페닐설피닐 또는 아실옥시알킬티오중에서 선택된다)이거나; (e) 디치환된 페닐(여기에서 치환체는 동일하고 C1-3알콕시, C1-2알킬설피닐, C2-31-알케닐-1-티오, 2-프로페닐-1-티오 또는 1-아실옥시-1-알킬티오이거나 치환체가 함께 메틸렌 디옥시그룹을 형성한다)인 방법.8. The compound of claim 7, wherein W is -CR 5 = CR 7- , -N = CR 7- , -S- or -O-, and R 2 and R 3 are hydrogen; Wherein one of R 1 and R 0 is 4-pyridyl or C 1-2 alkyl-4-pyridyl, provided that when R 1 is C 1-2 alkyl-4-pyridyl the alkyl substituent is at the 2-position of the pyridine ring And one of R 1 and R 0 is (a) monosubstituted phenyl, wherein the substituent is halo, CF 3 , C 1-3 alkylamino C 1-3 dialkalamino, thiol, hydroxy, C 1-3 alkoxy, C 1-3 alkylthio, C 1-3 alkylsulfinyl, acyloxyalkylthio or acylthio); (b) disubstituted phenyl, wherein the substituents are independently C 1-3 alkylthio, C 1-3 alkoxy, C 1-3 alkylamino, C 1-3 dialkylamino, N-pyrrolidino or N -Piperidino); (c) disubstituted phenyl, wherein one of the substituents is C 1-3 alkylsulfinyl, acylthio, 1-acyloxy-1-alkylthio and the other is C 1-3 alkoxy or halo ; (d) disubstituted phenyl, wherein one of said substituents is C 1-3 alkylamino, C 1-3 dialkylamino and the other is acylthio, alkylsulfinyl, phenylsulfinyl or acyloxyalkylthio Is selected); (e) disubstituted phenyl, wherein the substituents are the same and are C 1-3 alkoxy, C 1-2 alkylsulfinyl, C 2-3 1-alkenyl-1-thio, 2-propenyl-1-thio or 1-acyloxy-1-alkylthio or substituents together form a methylene dioxy group). 제8항에 있어서, W가 -CR5=CR7-, -N=CR7-이고; R2및 R3은 수소이고; R1및 R0중의 하나가 4-피리딜 또는 C1-2알킬-4-피리딜이며, 단, R1이 C1-2알킬-4-피리딜일 경우 알킬 치환체는 피리딘환의 2-위치에 위치하여야 하고, R1및 R0중의 다른 하나가 (a) 모노치환된 페닐(여기에서 상기치환체는 C1-3알콕시, C1-3알킬티오, C1-3알킬설피닐, 아실옥시알킬티오 또는 아실티오이다)이거나; (b) 디치환된 페닐(여기에서 상기 치환체는 독립적으로 C1-3킬틸오, C1-3알콕시, C1-3알킬아미노, 또는 C1-3디알킬아미노이다)이거나; (c) 디치환된 페닐(여기에서 상기 치환체중의 하나는 C1-3알킬설피닐, 아실티오, 1-아실옥시-1-알킬티오이고 다른하나는 C1-3알콕시 또는 할로이다)이거나; (d) 디치환된 페닐(여기에서 상기 치환체중의 하나는 C1-3알킬아미노, C1-3디알킬아미노이고 나머지는 아실티오, 알킬설피닐, 페닐설피닐 또는 아실옥시알킬티오중에서 선택된다)이거나; (e) 디치환된 페닐(여기에서 치환체는 동일하고 C1-3알콕시, C1-2알킬설피닐, C2-31-알케닐-1-티오, 2-프로페닐-1-티오 또는 1-아실옥시-1-알킬티오이거나 치환체가 함께 메틸렌 디옥시그룹을 형성한다)인 방법.9. The compound of claim 8, wherein W is -CR 5 = CR 7- , -N = CR 7- ; R 2 and R 3 are hydrogen; Wherein one of R 1 and R 0 is 4-pyridyl or C 1-2 alkyl-4-pyridyl, provided that when R 1 is C 1-2 alkyl-4-pyridyl the alkyl substituent is at the 2-position of the pyridine ring And one of R 1 and R 0 is (a) monosubstituted phenyl, wherein said substituent is C 1-3 alkoxy, C 1-3 alkylthio, C 1-3 alkylsulfinyl, acyloxyalkyl Thio or acylthio); (b) di-substituted phenyl, wherein the substituents are independently C 1-3 chethylo, C 1-3 alkoxy, C 1-3 alkylamino, or C 1-3 dialkylamino; (c) disubstituted phenyl, wherein one of the substituents is C 1-3 alkylsulfinyl, acylthio, 1-acyloxy-1-alkylthio and the other is C 1-3 alkoxy or halo ; (d) disubstituted phenyl, wherein one of said substituents is C 1-3 alkylamino, C 1-3 dialkylamino and the other is selected from acylthio, alkylsulfinyl, phenylsulfinyl or acyloxyalkylthio Or; (e) disubstituted phenyl, wherein the substituents are the same and are C 1-3 alkoxy, C 1-2 alkylsulfinyl, C 2-3 1-alkenyl-1-thio, 2-propenyl-1-thio or 1-acyloxy-1-alkylthio or substituents together form a methylene dioxy group). 제9항에 있어서, 일반식(I)의 화합물이 2-(4-메톡시페닐)-3-(4-피리딜)-이미다조[1,2-a]피리딘인 방법.The method of claim 9, wherein the compound of formula (I) is 2- (4-methoxyphenyl) -3- (4-pyridyl) -imidazo [1,2-a] pyridine. 제7항에 있어서, 사이클로옥시게나제 질병 상태가 피레시스, 통증, 골관절염, 류머티스성 관절염, 혈전증, 염증, 유티카리아 또는 부종인 방법.8. The method of claim 7, wherein the cyclooxygenase disease condition is pyresis, pain, osteoarthritis, rheumatoid arthritis, thrombosis, inflammation, uticaria or edema. OPUFA 개재된 질병의 치료를 필요로하는 환자에게 유효한 OPUFA 억제량의 2-(4-메톡시페닐)-3-(4-피리딜)-7-옥소-5,6-디히이드로-[7H]-피롤로[1,2-a]이미다졸; 5,6-디하이드로-2-(4-메톡시페닐)-3-(4-피리딜)-[7H]-피롤로[1,2-a]이미다졸-7-올; 또는 5,6-디하이드로-7,7-디플루오로-2-(4-메톡시페닐)-3-(4-피리딜)-[7H]-피롤로[1,2-a]이미다졸 또는 이의 약제학적으로 허용되는 염을 투여함을 특징으로 하여, 상기의 환자에 있어서 OPUFA 조절된 질병을 치료하는 방법.Amount of 2- (4-methoxyphenyl) -3- (4-pyridyl) -7-oxo-5,6-dihydro- [7H] effective in inhibiting OPUFA in patients in need of treatment for OPUFA intervening diseases -Pyrrolo [1,2-a] imidazole; 5,6-dihydro-2- (4-methoxyphenyl) -3- (4-pyridyl)-[7H] -pyrrolo [1,2-a] imidazol-7-ol; Or 5,6-dihydro-7,7-difluoro-2- (4-methoxyphenyl) -3- (4-pyridyl)-[7H] -pyrrolo [1,2-a] imidazole Or a pharmaceutically acceptable salt thereof, to treat an OPUFA modulated disease in said patient. 제12항에 있어서, OPUFA 개재된 질병이 관절염, 류머티스성 관절염, 골관절염, 진통성비염, 건선, 퍼부염, 국소빈혈 유도된 심근상처, 국소관류상처, 통풍, 천식, 성인호흡장애증후군, 아테롬성 동맥결화증, 염증성 장질환, 발작, 척추코드상처 또는 외상뇌상처인 방법.13. The method according to claim 12, wherein the disease mediated by OPUFA includes arthritis, rheumatoid arthritis, osteoarthritis, analgesic rhinitis, psoriasis, purpura, ischemia-induced myocardial wound, local perfusion wound, gout, asthma, adult respiratory distress syndrome, atherosclerosis A method that is a symptom, an inflammatory bowel disease, a seizure, a spinal cord injury or a traumatic brain injury. 제13항에 있어서, 효소 5-리프옥시게나제가 억제되는 방법.The method of claim 13, wherein the enzyme 5-lipoxygenase is inhibited. 사이클로옥시게나제 경로 개재된 질병의 치료를 필요로하는 환자에게 유효한 사이클로옥시게나제 억제량의 2-(4-메톡시페닐)-3-(4-피리딜)-7-옥소-5,6-디히이드로-[7H]-피롤로[1,2-a]이미다졸; 5,6-디하이드로-2-(4-메톡시페닐)-3-(4-피리딜)-[7H]-피롤로[1,2-a]이미다졸-7-올; 또는 5,6-디하이드로-7,7-디플루오로-2-(4-메톡시페닐)-3-(4-피리딜)-[7H]-피롤로[1,2-a]이미다졸 또는 이의 약제학적으로 허용되는 염을 투여함을 특징으로 하여, 상기의 환자에 있어서 OPUFA 조절된 질병을 치료하는 방법.A cyclooxygenase inhibitory amount of 2- (4-methoxyphenyl) -3- (4-pyridyl) -7-oxo-5,6 that is effective for patients in need of treatment of a disease interrupted by the cyclooxygenase pathway -Dihydro- [7H] -pyrrolo [1,2-a] imidazole; 5,6-dihydro-2- (4-methoxyphenyl) -3- (4-pyridyl)-[7H] -pyrrolo [1,2-a] imidazol-7-ol; Or 5,6-dihydro-7,7-difluoro-2- (4-methoxyphenyl) -3- (4-pyridyl)-[7H] -pyrrolo [1,2-a] imidazole Or a pharmaceutically acceptable salt thereof, to treat an OPUFA modulated disease in said patient. 일반식(II)의 화합물 또는 이의 약제학적으로 허용되는 염:Compound of Formula (II) or a pharmaceutically acceptable salt thereof: 상기식에서, W는 -CR2= CR7-, -N = CR7-, -S- 또는 -O-이고; R2, R3, R5및 R7는 독립적으로 수소 또는 C1-2알킬이고; T1및 T0중의 하나는 4-피리딜 또는 C1-4알킬-4-피리딜이며, 단, T1이 C1-4알킬-4-피리딜 경우 알킬 치환체는 피리딘환의 2-위치 위치하여야 하고, T1T0중의 다른 하나는 (a) 모노치환된 페닐[여기에서 상기 치환체는 하이드록시, C1-3알킬설포닐, C2-51-알케닐-1-설포닐, C3-52-알케닐-1-설포닐, C2-41-알케닐-1-설포닐, C3-52-알케닐-1-설포닐, C3-52-알케닐-1-설포닐, C1-3알킬아미노, C1-3디알킬아미노, CF3, N-C1-3알칸아미도, N-(C1-3알킬)-N-(C1-3알칸아미도), N-피롤리디노, N-피페리디노, 프로프-2-엔-1-옥시, 2,2,2-트리할로에톡시, 티올, 아실티오, 디티오아실, 티오카르바밀, 디티오카르바밀, 알킬카르보닐알킬티오, 카르브알콕시알킬티오, 알콕시카르보닐티오, 알콕시티오노티오, 페닐티오, 알콕시알킬티오, 알콕시알킬설피닐, 알콕시알킬티오, 또는 Z이다]이거나; (b) 디치환된 페닐[여기에서 상기 치환체중의 하나는 아미노, N-C1-3알칸아미노, N-(C1-3알킬)-N-(C1-3알칸아미도), C1-3알킬아미노, C1-3디알킬아미노, N-피롤리디노, 또는 N-피페리디노이고; 다른 치환체는 C1-3알킬설피닐, C2-51-알케닐-1-티오, C2-51-알케닐-1-설피닐, C3-52-알케닐-1-티오, C3-52-알케닐-1-설피닐, 티올, 아실티오, 디티오아실, 티오카르바밀, 디티오카르바밀, 알킬카르보닐알킬티오, 카르브알콕시알킬티오, 알콕시카르보닐티오, 알콕시티오노티오, 페닐티오, 알콕시알킬티오, 알콕시알킬설피닐, 알콕시알킬티오, 또는 Z, 또는 아실옥시알킬티오이다]이거나; (c) 디치환된 페닐(여기에서 상기 치환체는 동일하고 할로, C1-3알콕시, C1-3알킬아미노, C1-3디알킬 아미노, N-피롤리디노, N-피페리디노, 2,2,2-트리할로에톡시, 프로프-2-엔-1-옥시, 티올, 아실티오, 디티오아실, 티오카르바밀, 디티오카르바밀, 알킬카르보닐알킬티오, 카르브알콕시알킬티오, 알콕시카르보닐티오, 알콕시티오노티오, 페닐티오, 알콕시알킬티오, 알콕시알킬설피닐, 알킬티오알킬티오 또는 Z이다)이거나; (d) 디치환된 페닐[여기에서 상기 치환체는 독립적으로 C1-3알킬아미노, C1-3디알킬아미노, 아미노, N-(C1-3알킬)-N-(C1-3알칸아미도), N-피롤리디노 또는 N-피페리디노이다)이거나; (e) 다음 일반식중의 하나의 잔기이다:Wherein W is -CR 2 = CR 7- , -N = CR 7- , -S- or -O-; R 2 , R 3 , R 5 and R 7 are independently hydrogen or C 1-2 alkyl; One of T 1 and T 0 is 4-pyridyl or C 1-4 alkyl-4-pyridyl, provided that when T 1 is C 1-4 alkyl-4-pyridyl the alkyl substituent is the 2-position of the pyridine ring And the other of T 1 T 0 is (a) monosubstituted phenyl, wherein the substituent is hydroxy, C 1-3 alkylsulfonyl, C 2-5 1-alkenyl-1-sulfonyl, C 3-5 2-alkenyl-1-sulfonyl, C 2-4 1-alkenyl-1-sulfonyl, C 3-5 2-alkenyl-1-sulfonyl, C 3-5 2-alkenyl- 1-sulfonyl, C 1-3 alkylamino, C 1-3 dialkylamino, CF 3 , NC 1-3 alkanamido, N- (C 1-3 alkyl) -N- (C 1-3 alkanami Fig.), N-pyrrolidino, N-piperidino, prop-2-en-1-oxy, 2,2,2-trihaloethoxy, thiol, acylthio, dithioacyl, thiocarbamyl , Dithiocarbamyl, alkylcarbonylalkylthio, carboalkoxyalkylthio, alkoxycarbonylthio, alkoxythioothio, phenylthio, alkoxyalkylthio, alkoxyalkylsulfinyl, alkoxyalkylthio, or Z] Or; (b) disubstituted phenyl [where one of the substituents is amino, NC 1-3 alkanamino, N- (C 1-3 alkyl) -N- (C 1-3 alkanamido), C 1- 3 alkylamino, C 1-3 dialkylamino, N-pyrrolidino, or N-piperidino; Other substituents include C 1-3 alkylsulfinyl, C 2-5 1-alkenyl-1-thio, C 2-5 1-alkenyl-1-sulfinyl, C 3-5 2-alkenyl-1-thio , C 3-5 2-alkenyl-1-sulfinyl, thiol, acylthio, dithioacyl, thiocarbamyl, dithiocarbamyl, alkylcarbonylalkylthio, carbalkoxyalkylthio, alkoxycarbonylthio, Alkoxythiothiothio, phenylthio, alkoxyalkylthio, alkoxyalkylsulfinyl, alkoxyalkylthio, or Z, or acyloxyalkylthio; (c) disubstituted phenyl, wherein said substituents are the same and halo, C 1-3 alkoxy, C 1-3 alkylamino, C 1-3 dialkyl amino, N-pyrrolidino, N-piperidino, 2,2,2-trihaloethoxy, prop-2-ene-1-oxy, thiol, acylthio, dithioacyl, thiocarbamyl, dithiocarbamyl, alkylcarbonylalkylthio, carvalkoxy Alkylthio, alkoxycarbonylthio, alkoxythiothiothio, phenylthio, alkoxyalkylthio, alkoxyalkylsulfinyl, alkylthioalkylthio or Z); (d) disubstituted phenyl, wherein the substituents are independently C 1-3 alkylamino, C 1-3 dialkylamino, amino, N- (C 1-3 alkyl) -N- (C 1-3 alkanes) Amido), N-pyrrolidino or N-piperidino); (e) is a residue of one of the following general formulas: 상기식에서, t는 0 또는 1이고; R4는 R6는 독립적으로 수소, C1-9알킬, 아릴 또는 헤테로아릴이고; Z는 -S-(CR4R6)t-S-Z1이고; Z1는 C1-9알킬, 아릴 또는 헤테로아릴이다.Wherein t is 0 or 1; R 4 is R 6 is independently hydrogen, C 1-9 alkyl, aryl or heteroaryl; Z is -S- (CR 4 R 6 ) t -SZ 1 ; Z 1 is C 1-9 alkyl, aryl or heteroaryl. 제16항의 화합물 및 약제학적으로 허용되는 담체 또는 희석제를 함유하는 약제학적 조성물.A pharmaceutical composition comprising the compound of claim 16 and a pharmaceutically acceptable carrier or diluent. OPUFA 개재된 질병의 치료를 요하는 포유동물에게 유효한 OPUFA 억제량의 제16항에 따르는 화합물을 투여함을 특징으로 하여, 포유동물에 있어서 OOPUFA 개재된 질병을 치료하는 방법.A method for treating an OOPUFA mediated disease in a mammal, characterized by administering a compound according to claim 16 of an effective amount of OPUFA inhibition to a mammal in need of treatment of the OPUFA mediated disease. 제18항에 있어서, 효소-5-리프옥시게나제를 억제시키는 방법.19. The method of claim 18, wherein the enzyme-5-lipoxygenase is inhibited. 약제학적으로 허용되는 담체 또는 희석제 및 일반식(III)의 화합물 및 이의 약제학적으로 허용되는 염을 함유하는 OPUFA 또는 사이클로옥시게나제 개재된 질병상태의 치료용 약제학적 조성물:A pharmaceutical composition for the treatment of a disease state mediated by OPUFA or cyclooxygenase containing a pharmaceutically acceptable carrier or diluent and a compound of formula (III) and a pharmaceutically acceptable salt thereof: 상기식에서, W는 -CR5= CR7-, -N = CR7-, -S- 또는 -O-이고; R2, R3, R5및 R7는 독립적으로 수소 또는 C1-2알킬이고; S1및 S0중의 하나는 4-피리딜 또는 C1-4알킬-4-피리딜이며; 단, S1이 C1-4알킬-4-피리딜인 경우 알킬 치환체는 피리딘환의 2-위치 위치하여야 하고, (a) 모노치환된 페닐(여기에서 상기 치환체는 수소, C1-4알킬, 할로, C1-2알콕시, C1-3알킬티오, C1-3알킬설피닐, C2-51-알케닐-1-티오, C2-51-알케닐-1-설피닐, C3-52-알케닐-1-티오, C3-52-알케닐-1-설피닐 또는 알실옥시알킬티오이다)이거나; (b) 디치환된 페닐(여기에서 상기 치환체는 독립적으로 C1-3알킬티오, C1-3알콕시, 할로 또는 C1-4알킬이다)이거나; (c) 디치환된 페닐(여기에서 상기 치환체중의 하나는 C1-3알콕시, 할로, 또는 C1-4알킬이고; 다른 하나는 C1-3알킬설피닐, C2-51-알케닐-1-티오, C2-51-알케닐-1-설피닐, C3-52-알케닐-1-티오, C1-32-알케닐-1-설피닐 또는 아실옥시알킬티오이다)이거나; (d) 디치환된 페닐(여기에서 상기 치환체는 동일하고 C1-3알킬설피닐, C2-51-알케닐-1-티오, C2-51-알케닐-1-설피닐, C3-52-알케닐-1-티오,3-52-알케닐-1-설피닐 또는 아실옥시알킬티오이거나 치환제가 함께 메켈렌 디옥시를 형성한다)이다.Wherein W is -CR 5 = CR 7- , -N = CR 7- , -S- or -O-; R 2 , R 3 , R 5 and R 7 are independently hydrogen or C 1-2 alkyl; One of S 1 and S 0 is 4-pyridyl or C 1-4 alkyl-4-pyridyl; Provided that when S 1 is C 1-4 alkyl-4-pyridyl the alkyl substituent should be in the 2-position of the pyridine ring, and (a) monosubstituted phenyl (wherein the substituent is hydrogen, C 1-4 alkyl, Halo, C 1-2 alkoxy, C 1-3 alkylthio, C 1-3 alkylsulfinyl, C 2-5 1-alkenyl-1-thio, C 2-5 1-alkenyl-1-sulfinyl, C 3-5 2-alkenyl-1-thio, C 3-5 2-alkenyl-1-sulfinyl or alyloxyalkylthio; (b) disubstituted phenyl, wherein the substituents are independently C 1-3 alkylthio, C 1-3 alkoxy, halo or C 1-4 alkyl; (c) disubstituted phenyl, wherein one of the substituents is C 1-3 alkoxy, halo, or C 1-4 alkyl; the other is C 1-3 alkylsulfinyl, C 2-5 1-al Kenyl-1-thio, C 2-5 1-alkenyl-1-sulfinyl, C 3-5 2-alkenyl-1-thio, C 1-3 2-alkenyl-1-sulfinyl or acyloxyalkyl Thio); (d) disubstituted phenyl, wherein the substituents are the same and are C 1-3 alkylsulfinyl, C 2-5 1-alkenyl-1-thio, C 2-5 1-alkenyl-1-sulfinyl, C 3-5 2-alkenyl-1-thio, 3-5 2-alkenyl-1-sulfinyl or acyloxyalkylthio or the substituents together form mechelene dioxy). 약제학적으로 허용되는 담체 또는 희석제 및 2-(4-메톡시페닐)-3-(4-피리딜)-7-옥소-5,6-디히이드로-[7H]-피롤로[1,2-a]이미다졸; 5,6-디하이드로-2-(4-메톡시페닐)-3-(4-피리딜)-[7H]-피롤로[1,2-a]이미다졸-7-올; 또는 5,6-디하이드로-7,7-디플루오로-2-(4-메톡시페닐)-3-(4-피리딜)-[7H]-피롤로[1,2-a]이미다졸 중에서 선택된 하나의 화합물 또는 이의 약제학적으로 허용되는 염을 함유하는, OPUFA 개재된 질병 치료용 약제학적 조성물.Pharmaceutically acceptable carriers or diluents and 2- (4-methoxyphenyl) -3- (4-pyridyl) -7-oxo-5,6-dihydro- [7H] -pyrrolo [1,2- a] imidazole; 5,6-dihydro-2- (4-methoxyphenyl) -3- (4-pyridyl)-[7H] -pyrrolo [1,2-a] imidazol-7-ol; Or 5,6-dihydro-7,7-difluoro-2- (4-methoxyphenyl) -3- (4-pyridyl)-[7H] -pyrrolo [1,2-a] imidazole A pharmaceutical composition for treating an OPUFA-interposed disease, containing one compound selected from the group or a pharmaceutically acceptable salt thereof. 헤테로 방향족질소함유 환계상의 치환체그룹인 아릴설파이드를 수성아세트산 중에서 과황산 나트륨 또는 과황상 칼륨으로 처리하여[단, 산화제가 과황산 칼륨인 경우 헤테로방항족 환이 2-(C1-3알킬설파이드페닐)-3-(4-피리딜)-6,7-디하이드로-[5H]-피롤로[2,1-a]이미다졸환계가 아니어야한다]상응하는 아릴설폭사이드 유도체를 생성시킴을 특징으로 하여, 상기 아릴설파이드를 아릴설폭사이드로 산화시키는 방법.Of the substituent group of a nitrogen-containing heteroaromatic ring boundary aryl sulfide by treatment with aqueous acetic acid and sulfuric acid from sodium or potassium and hwangsang [stage, the oxidizing agent is potassium persulfate and when the hetero ring room hangjok 2- (C 1-3 alkyl phenyl sulfide ) -3- (4-pyridyl) -6,7-dihydro- [5H] -pyrrolo [2,1-a] imidazol ring system] to produce a corresponding arylsulfoxide derivative To oxidize the aryl sulfide to aryl sulfoxide. 제22항에 있어서, 아릴 설파이드가 페닐설파이드 잔기인 방법.The method of claim 22, wherein the aryl sulfide is a phenylsulfide moiety. 제23항에 있어서, 아릴 설파이드가 알킬 또는 아릴 치환된 설파이드인 방법.The method of claim 23, wherein the aryl sulfide is alkyl or aryl substituted sulfide. 제24항에 있어서, 알킬 치환된 설파이드가 메틸티오 또는 에틸티오인 방법.The method of claim 24, wherein the alkyl substituted sulfide is methylthio or ethylthio. 제25항에 있어서, 산화제가 과황산 칼륨인 방법.The method of claim 25, wherein the oxidant is potassium persulfate. 제26항에 있어서, 산화제가 과황산 나트륨인 방법.27. The method of claim 26, wherein the oxidant is sodium persulfate. 제26항 또는 제27항에 있어서, 반응온도가 약 0℃ 내지 약 60℃인 방법.The method of claim 26 or 27, wherein the reaction temperature is between about 0 ° C. and about 60 ° C. 29. 제22항에 있어서, 아세톤 또는 THF와 같은 추가의 공용매를 사용하는 방법.The method of claim 22 wherein additional cosolvents such as acetone or THF are used. 제22항에 있어서, 질소함유 헤테로방향족 환계가 피롤로, 피라졸, 이미다졸, 이미다졸리디딘, 피라졸리딘, 피라졸린, 모르폴린, 피리딘, 피라진, 인돌리진, 인돌린, 퓨린, 퀴놀린, 이소퀴놀린, 나프티리딘, 트리아졸, 피리디민, 피페리딘, 이소인돌, 3H-인돌, 시놀린, 카바졸, 페난트라딘, 페나진, 이소티아졸, 이미다조[1,2-b)-[1,2,4)트리아진, 트리아진, 피리다진, 6,7-디하이드로-[5H]-피롤로[2,1-a]이미다졸, 2,3-디하이드로이미다조[2,1-b)티아졸, 이미다조[2,1-b]옥사졸, 이미다조[1,2-a]피리딘, 5,6,7,8-테트라하이드로이미다조[1,2-a]-피리딘 또는 이미다조[1,2-a]피리미딘 환계중에서 선택되는 방법.23. The method of claim 22, wherein the nitrogen-containing heteroaromatic ring system is pyrrolo, pyrazole, imidazole, imidazolididine, pyrazolidine, pyrazoline, morpholine, pyridine, pyrazine, indolizin, indolin, purine, quinoline, Isoquinoline, naphthyridine, triazole, pyrididimine, piperidine, isoindole, 3H-indole, cynoline, carbazole, phenanthradine, phenazine, isothiazole, imidazo [1,2-b)- [1,2,4) triazine, triazine, pyridazine, 6,7-dihydro- [5H] -pyrrolo [2,1-a] imidazole, 2,3-dihydroimidazo [2, 1-b) thiazole, imidazo [2,1-b] oxazole, imidazo [1,2-a] pyridine, 5,6,7,8-tetrahydroimidazo [1,2-a]- Pyridine or imidazo [1,2-a] pyrimidine ring system. 제22항에 있어서, 산화제가 과황산나트륨이고 헤테로방향족 질소함유환이 3-(4-피리딜)-6,7-디하이드로-[5H]-피롤로[2,1-a]이미다졸 환이고 아릴설파이드가 2-메틸티오페닐 또는 2-프로필티오페닐인 방법23. The compound of claim 22, wherein the oxidant is sodium persulfate and the heteroaromatic nitrogen-containing ring is a 3- (4-pyridyl) -6,7-dihydro- [5H] -pyrrolo [2,1-a] imidazole ring and aryl The sulfide is 2-methylthiophenyl or 2-propylthiophenyl ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019920703188A 1990-06-12 1991-06-07 Inhibition of diseases mediated by the 5-lipoxygenase and cyclooxygenase pathways KR930700104A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53719590A 1990-06-12 1990-06-12
US537,195 1990-06-12
PCT/US1991/004022 WO1991019497A1 (en) 1990-06-12 1991-06-07 Inhibition of 5-lipoxygenase and cyclooxygenase pathway mediated diseases

Publications (1)

Publication Number Publication Date
KR930700104A true KR930700104A (en) 1993-03-13

Family

ID=24141624

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920703188A KR930700104A (en) 1990-06-12 1991-06-07 Inhibition of diseases mediated by the 5-lipoxygenase and cyclooxygenase pathways

Country Status (10)

Country Link
EP (1) EP0533837A4 (en)
JP (1) JPH05508153A (en)
KR (1) KR930700104A (en)
AU (1) AU8205991A (en)
CA (1) CA2084290A1 (en)
IE (1) IE911977A1 (en)
NZ (1) NZ238485A (en)
PT (1) PT97960A (en)
WO (1) WO1991019497A1 (en)
ZA (1) ZA914491B (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0679396A1 (en) * 1994-03-02 1995-11-02 Pfizer Inc. Use of 3-substituted-2-oxidole-1-carboxamides for the manufacture of a medicament in the treatment and prevention of ischemia induced myocardial injury and cytokine mediated myocardial injury
US5552422A (en) * 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
CA2224517A1 (en) * 1995-06-12 1996-12-27 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
WO1999012930A1 (en) 1997-09-05 1999-03-18 Glaxo Group Limited 2,3-diaryl-pyrazolo[1,5-b]pyridazines derivatives, their prepa ration and their use as cyclooxygenase 2 (cox-2) inhibitors
WO1999032121A1 (en) 1997-12-19 1999-07-01 Smithkline Beecham Corporation Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
CA2341370A1 (en) 1998-08-20 2000-03-02 Smithkline Beecham Corporation Novel substituted triazole compounds
PL348208A1 (en) 1998-11-03 2002-05-06 Glaxo Group Ltd Pyrazolopyridine derivatives as selective cox-2 inhibitors
DE69914357T2 (en) 1998-11-04 2004-11-11 Smithkline Beecham Corp. PYRIDIN-4-YL OR PYRIMIDIN-4-YL SUBSTITUTED PYRAZINE
AU2661400A (en) 1999-02-27 2000-09-21 Glaxo Group Limited Pyrazolopyridines
SK9892001A3 (en) * 1999-11-10 2002-04-04 Ortho Mcneil Pharm Inc Substituted 2-aryl-3-(heteroaryl)-imidazo[1,2-a]pyrimidines, and related pharmaceutical compositions and methods
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
US7053098B1 (en) 1999-11-23 2006-05-30 Smithkline Beecham Corporation 3,4-Dihydro-(1H) quinazolin-2-one compounds as CSBP/P38 kinase inhibitors
JP2003514899A (en) 1999-11-23 2003-04-22 スミスクライン・ビーチャム・コーポレイション 3,4-Dihydro- (1H) -quinazolin-2-one compounds as CSBP / p38 kinase inhibitors
AU1782301A (en) 1999-11-23 2001-06-04 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p39 kinase inhibitors
GB9930358D0 (en) 1999-12-22 2000-02-09 Glaxo Group Ltd Process for the preparation of chemical compounds
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
PE20020506A1 (en) 2000-08-22 2002-07-09 Glaxo Group Ltd PIRAZOLE DERIVATIVES FUSED AS PROTEIN KINASE INHIBITORS
US6919352B2 (en) 2000-12-15 2005-07-19 Smithkline Beecham Corporation Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds
DE60112330T2 (en) 2000-12-15 2006-04-13 Glaxo Group Ltd., Greenford pyrazolopyridine derivatives
WO2002072581A2 (en) 2001-03-08 2002-09-19 Smithkline Beecham Corporation Pyrazolopyriadine derivatives
US6596731B2 (en) 2001-03-27 2003-07-22 Hoffmann-La Roche Inc. Substituted imidazo[1,2-A] pyridine derivatives
US7034030B2 (en) 2001-03-30 2006-04-25 Smithkline Beecham Corporation Pyralopyridines, process for their preparation and use as therapeutic compounds
DE60212949T2 (en) 2001-04-10 2007-01-04 Smithkline Beecham Corp. ANTIVIRAL PYRAZOLOPYRIDINE COMPOUNDS
US6756498B2 (en) 2001-04-27 2004-06-29 Smithkline Beecham Corporation Process for the preparation of chemical compounds
ES2242028T3 (en) 2001-04-27 2005-11-01 Smithkline Beecham Corporation DERIVATIVES OF PIRAZOLO (1,5-A) PIRIDINA.
CN1518550A (en) * 2001-06-21 2004-08-04 ʷ��˿�������ȳ�ķ���޹�˾ Imidazo [1,2-A] pyridine derivatives for prophylaxis and treatment of herpes viral infections
ATE326466T1 (en) 2001-10-05 2006-06-15 Smithkline Beecham Corp IMIDAZOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HERPES VIRUS INFECTION
JP2005516916A (en) 2001-12-11 2005-06-09 スミスクライン ビーチャム コーポレーション Pyrazolo-pyridine derivatives as anti-herpes drugs
US7153863B2 (en) 2002-10-03 2006-12-26 Smithkline Beecham Corporation Therapeutic compounds based on pyrazolopyridline derivatives
US7709468B2 (en) 2005-09-02 2010-05-04 Abbott Laboratories Imidazo based heterocycles
EP2170337A4 (en) 2007-06-28 2013-12-18 Abbvie Inc Novel triazolopyridazines
KR101774035B1 (en) 2009-10-30 2017-09-01 얀센 파마슈티카 엔.브이. IMIDAZO[l,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE1O INHIBITORS
CN102781930B (en) 2009-12-18 2016-03-23 田边三菱制药株式会社 Antiplatelet drug
AR080754A1 (en) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv IMIDAZO DERIVATIVES (1,2-A) PIRAZINA AND ITS USE AS PDE10 INHIBITORS
CN106986862A (en) 2010-12-22 2017-07-28 Abbvie 公司 Hepatitis c inhibitor and application thereof
AU2012277912B2 (en) 2011-06-27 2017-03-23 Janssen Pharmaceutica Nv 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives
CA2872216C (en) 2012-06-26 2021-07-20 Janssen Pharmaceutica Nv Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl-[1,2,4] triazolo [4,3-a] quinoxaline compounds and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders
CN104411314B (en) 2012-07-09 2017-10-20 詹森药业有限公司 The inhibitor of phosphodiesterase 10

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZW24186A1 (en) * 1985-12-12 1987-07-08 Smithkline Beckman Corp Inhibition of the 5-lipoxygenase pathway
US5002941A (en) * 1985-12-12 1991-03-26 Smithkline Beecham Corporation Pyrrolo(1,2-a)imidazole and imidazo(1,2-a)pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors
WO1991000092A1 (en) * 1989-06-13 1991-01-10 Smithkline Beecham Corporation Inhibition of interleukin-1 and tumor necrosis factor production by monocytes and/or macrophages

Also Published As

Publication number Publication date
NZ238485A (en) 1994-03-25
ZA914491B (en) 1992-12-30
PT97960A (en) 1992-03-31
CA2084290A1 (en) 1991-12-13
AU8205991A (en) 1992-01-07
JPH05508153A (en) 1993-11-18
IE911977A1 (en) 1991-12-18
EP0533837A4 (en) 1994-11-17
WO1991019497A1 (en) 1991-12-26
EP0533837A1 (en) 1993-03-31

Similar Documents

Publication Publication Date Title
KR930700104A (en) Inhibition of diseases mediated by the 5-lipoxygenase and cyclooxygenase pathways
AU2020257163B2 (en) Small molecule inhibitors of lactate dehydrogenase and methods of use thereof
AU697650B2 (en) Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
AU2009319048B2 (en) Pharmaceutical combination comprising a Hsp 90 inhibitor and a mTOR inhibitor
US6803380B1 (en) 5-aryl-1h-1,2,4-triazole compounds as inhibitors of cyclooxygenase-2 and pharmaceutical compositions containing them
FI66390C (en) REFERENCE FOR THERAPEUTIC USE OF THERAPEUTIC THERAPEUTIC IMMEDIATE (2,1-B) (1,3,4) -TIADIAZOLER
CS208747B2 (en) Method of making the7-(alfa-oximino-alfa-(2-aminothiazol-4-yl)acetamido/cefalosporan acids and derivatives thereof
DE2716677A1 (en) CEPHEM DERIVATIVES AND METHOD FOR THEIR PRODUCTION
SE8106404L (en) penicillin derivatives
RU2001102777A (en) Oxazole, thiazole and selenazole [4,5-C] -quinoline-4-amines and their analogs
RU2000128033A (en) Heterocyclic derivatives of glycyl-beta-alanine as vitronectin antagonists
Cullen Novel anti-inflammatory agents
ES2332137T3 (en) PRODUCT THAT INCLUDES AT LEAST A CDC25 PHOSPHATASE INHIBITOR IN ASSOCIATION WITH AT LEAST ANOTHER ANTI-TARGET AGENT.
EP0883622A1 (en) Proton pump inhibitor
US4762848A (en) 1,3-thiazoles and their use as immunomodulators
NO764054L (en)
RU2000111469A (en) Production and use of ortho-sulfonamidobicyclic heteroaryl hydroxy acids as inhibitors of matrix metalloproteinases of matrix and tase (TNF-alpha-converting enzyme)
KR900003167A (en) Their use as pyrrolo [1,2, -a] imidazole and pyrrolo [1,2-a] pyridine derivatives and 5-lipoxygenase pathway inhibitors
KR900001701A (en) Use of imidazopyrazole derivatives as analgesics and anti-inflammatory agents
US3519716A (en) Treatment of hyperuricemia in mammals,using mercapto-substituted pyrazolo(3,4-d)-pyrimidines
DD142053A5 (en) METHOD FOR THE PRODUCTION OF NEW THIENO SQUARE BRACKET ON 3,2-C SQUARE BRACKET AND THIENOOUS BRACKET ON 2,3-C CORNER BRACKET TO PYRIDINES
AT359195B (en) METHOD FOR PRODUCING NEW CEPHALOS PORINE COMPOUNDS AND THEIR PHARMACEUTICAL APPLICABLE SALTS
FI863986A (en) NYA 2- (2-THIENYL) -IMIDAZO (4,5-C) PYRIDINDERIVAT OCH DERAS SALTER, FOERFARANDE FOER DERAS FRAMSTAELLNING OCH DESSA INNEHAOLLANDE PHARMACEUTICAL PREPARATION.
MXPA00000223A (en) Fused 1,2,4-thiadiazine derivatives, their preparation and use
RU98109784A (en) PHARMACEUTALLY ACTIVE QUINASOLINE DERIVATIVES

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid